Wall Street Zen upgraded shares of Pfizer (NYSE:PFE – Free Report) from a hold rating to a buy rating in a report issued on Saturday morning,Wall Street Zen reports.
Several other analysts have also commented on the company. Freedom Broker increased their price objective on Pfizer from $33.00 to $34.00 and gave the company a “buy” rating in a report on Friday, November 6th. FBN Securities set a $34.00 target price on Pfizer in a research note on Friday, November 6th. HSBC upped their target price on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Cantor Fitzgerald increased their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Finally, Weiss Ratings upgraded Pfizer from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. Six analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $30.32.
Check Out Our Latest Stock Analysis on PFE
Pfizer Stock Up 0.2%
NYSE:PFE traded up $0.06 during midday trading on Friday, reaching $28.89. 21,545,367 shares of the stock traded hands, compared to its average volume of 35,571,128. Pfizer has a 12-month low of $23.62 and a 12-month high of $31.44. The business has a 50-day moving average of $28.80 and a two-hundred day moving average of $26.98. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42. The stock has a market capitalization of $164.65 billion, a PE ratio of 41.27, a price-to-earnings-growth ratio of 1.89 and a beta of 0.31.
Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period last year, the firm earned $0.87 earnings per share. Pfizer’s revenue was down .4% compared to the same quarter last year. On average, equities analysts forecast that Pfizer will post 3.04 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. Pfizer’s dividend payout ratio (DPR) is 245.71%.
Institutional Trading of Pfizer
Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new stake in Pfizer during the 2nd quarter valued at approximately $1,049,602,000. BlackRock Inc. boosted its holdings in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. Nykredit A S acquired a new stake in shares of Pfizer in the second quarter worth $205,774,000. Assenagon Asset Management S.A. increased its stake in shares of Pfizer by 96.0% in the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after acquiring an additional 5,829,204 shares during the period. Finally, State Street Corp raised its holdings in shares of Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.
Pfizer News Summary
Here’s some of the latest news about PFE:
- Positive Sentiment: Pfizer raised its 2026 revenue forecast by $1.5 billion, a constructive outlook signal. The company had also beaten Q3 earnings and revenue expectations, though investors did not respond positively to the results. Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion
- Neutral Sentiment: Pfizer’s high dividend yield may attract income investors, but commentary cautions that a record-high yield can also reflect concerns about the sustainability of the payout. A Record-High Dividend Yield Can Be a Warning Sign
- Negative Sentiment: Pfizer will stop selling Premarin hormone therapy in Canada after an internal review, adding to existing menopause-drug shortages and removing a product from that market. Pfizer to Stop Selling Premarin Hormone Therapy in Canada
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Further Reading
- Five stocks we like better than Pfizer
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
